AS1411 aptamer based nanomaterials: A novel approach for breast cancer therapy [0.03%]
基于AS1411适配体的纳米材料：乳腺癌治疗的新方法
Yashasvi Verma,Insha Khan,Tenzin Tsering Dongsar et al.
Yashasvi Verma et al.
AS1411 aptamer-based nanomaterials have emerged as a transformative solution, leveraging the aptamer's high-affinity binding to nucleolin, a receptor overexpressed on breast cancer cells, to enable targeted drug delivery, imaging, and combinatorial therapies....These advancements highlight the multifunctional potential of AS1411-based nanoformulations in advancing breast cancer treatment, which combine precise targeting with reduced systemic toxicity, and compatibility....Collaborative efforts to optimize scalable manufacturing and conduct comprehensive immunotoxicity studies will be pivotal in advancing these nanotherapeutics from preclinical promise to clinical reality, ultimately offering a safer, more effective paradigm for breast cancer treatment.
A cGAS-STING pathway activating cobalt(III) cyclam prodrug for combined chemotherapy and immunotherapy of breast cancer [0.03%]
一种用于联合化疗和免疫治疗乳腺癌的cGAS-STING途径激活钴(III)环氨醇前药
Haiqin Song,Nicolás Montesdeoca,Elizaveta Efanova et al.
Haiqin Song et al.
Upon injection into the blood stream, the nanoparticles accumulated in the triple-negative breast cancer tumor of the mouse model, activated the immune response inside the animal, and caused a nearly complete eradication of the tumor.
The novel diarylurea derivative HPT-15 for potential treatment of triple-negative breast cancer via dual inhibition of the mTOR and MAPK pathways [0.03%]
一种新型二芳基脲衍生物HPT-15通过抑制mTOR和MAPK途径联合治疗三阴性乳腺癌的潜力研究
Yujie Wang,Huanhuan Wu,Jiale Luo et al.
Yujie Wang et al.
Dysregulation of the mTOR serine/threonine protein kinase has been linked to the pathogenesis and prognosis of triple-negative breast cancer (TNBC). Meanwhile, the MAPK signaling pathway has been implicated in the progression and drug resistance of TNBC.
Reduced JAG1 Expression Through miR-200 Overexpression or Crispr-Cas Mediated Knockout Impairs TNBC Growth and Metastasis [0.03%]
miR-200过表达或CRISPR-Cas介导的敲除JAG1抑制三阴性乳腺癌的生长和转移
Megan Vaz,Katrina L Watson,Roger A Moorehead
Megan Vaz
Studies from our lab demonstrated that increasing miR-200 expression in human triple negative breast cancer (TNBC) reduced tumor growth and metastasis In Vivo. In this study, we found that overexpression of miR-200s in TNBC cells significantly reduced the expression of JAG1.
A disposable VHH-based SPR fiber probe for sensitive and specific detection of MMP-9 in cancer and inflammatory disease [0.03%]
一种基于VHH的SPR光纤探针用于癌症和炎症疾病中敏感且特异的MMP-9检测
Dandan Wu,Jian Yang,Junxiao Cong et al.
Dandan Wu et al.
This disposable VHH-based SPR fiber probe enables sensitive MMP-9 quantification in various cancer cell lines as well as tissue and serum specimens from murine models of colorectal and breast cancer and dextran sulfate sodium (DSS)-induced colitis....Clinical validation using human samples demonstrated successful MMP-9 detection in breast cancer and IBD cohorts.
Double trouble: Tumor-to-tumor metastasis of breast cancer into a thyroid papillary carcinoma - Case report and review of literature [0.03%]
双肿瘤麻烦：乳腺癌转移到甲状腺乳头状瘤的病例报告和文献综述
Souheil Jbali,Amani Amri,Mohamed Dhaha et al.
Souheil Jbali et al.
Clinical discussion: Metastatic breast cancer to the thyroid accounts for only 1 %-3 % of all thyroid malignancies, despite the thyroid's rich vascularity. These metastases can mimic a primary thyroid tumor....Despite its rarity, awareness of this entity is crucial and requires close thyroid monitoring in breast cancer survivors.
Targeting monopolar spindle kinase I (Mps1 or TTK) induces radiosensitization in syngeneic models of triple negative breast cancer (TNBC) and potentiates type I interferon (T1IFN) signaling [0.03%]
靶向单极纺锤体激酶I（Mps1或TTK）可使同基因三阴性乳腺癌（TNBC）模型放射增敏并增强I型干扰素（T1IFN）信号转导
Kassidy M Jungles,Caroline R Bishop,Cydnee M Wilson et al.
Kassidy M Jungles et al.
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that disproportionately impacts Black women and has limited effective therapeutic options. Consequently, there is an urgent need to develop novel approaches for the treatment of TNBC.
Correction: ENABLE-App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial [0.03%]
纠正：ENABLE 基于应用程序的数字患者报告的生活质量、不良事件和治疗满意度捕获及干预乳腺癌随机对照试验方案
Thomas M Deutsch,Léa L Volmer,Manuel Feisst et al.
Thomas M Deutsch et al.
[This corrects the article DOI: 10.2196/69855.]. ©Thomas M Deutsch, Léa L Volmer, Manuel Feisst, Laura Bodenbeck, Kathrin Hassdenteufel, Lara Tretschoc...
Published Erratum
JMIR research protocols. 2025 Jun 11:14:e78781. DOI:10.2196/78781 2025
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas [0.03%]
用于治疗晚期或转移性实体瘤或淋巴瘤的STING激动剂Ulev ostina与帕博利珠单抗联合使用的1/2期临床研究
Kevin J Harrington,Stephane Champiat,Joshua D Brody et al.
Kevin J Harrington et al.
In an expansion phase, participants with head and neck squamous cell carcinoma (HNSCC) or triple-negative breast cancer received the combination. Primary objectives were safety/tolerability and identifying the recommended phase 2 dose (RP2D); biomarkers were exploratory.
EMOTION: Assessing the Impact of a Telephone Intervention for Patients With Breast Cancer, a Randomized Controlled Trial [0.03%]
情绪评估：一项针对乳腺癌患者的电话干预随机对照试验
Sara Contu,Christophe Hebert,Jean-Marc Ferrero et al.
Sara Contu et al.
Purpose: Breast cancer diagnosis and treatment cause psychosocial distress that can worsen the disease course and outcomes. We hypothesized that personalized telephone follow-up would reduce stress and anxiety, enhance pa...
耗时 0.37666 秒，为您在
48206918
条记录里面共找到 10000 篇文章 [XML]